The once-daily, fixed dose combination of drugs is showing promise for treating all forms of hepatitis C. Gilead is testing the treatment in four late-stage studies.
Three trials involved 1,053 patients treated with the drug for 12 weeks. Of these patients, 98 percent were cured, according to the report. The fourth trial involved patients with more advanced forms of HCV. In this trial, Gilead’s combination drug resulted in higher cure rates than ribavirin.
More articles on gastroenterology:
8 things to know about the burden of GI, liver diseases
FDA clears 6 GI/endoscopy devices in August
Advanced Gastroenterology joins Greater Houston Gastroenterology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.